"The patient's perspective of the clinical utility of second-line chemotherapy"

Project Summary and Objectives:

There is a well-recognised mismatch between the perceptions of cancer patients and non-cancer sufferers, in terms of the benefits of first-line palliative chemotherapy.
Attitudes of patients and doctors to second-line chemotherapy, which usually has a low response rate and is often toxic and expensive, now require examination.
Patients with ovarian cancer, small cell lung cancer and breast cancer, where second-line chemotherapy is frequently used, will be studied, as will control groups of normal subjects, General Practitioners and cancer specialists.
Subjects will be asked to assess their personal cost-benefit of second-line chemotherapy by indicating the degree of benefit from a hypothetical treatment which would be more acceptable.
The influence of prior chemotherapy experience on decision-making will be assessed, as will the acceptability of best supportive care as an alternative to second-line chemotherapy.
Re-examination of patients after second-line chemotherapy will be performed.

The investigation aims to measure the clinical efficacy of second-line chemotherapy in advanced cancer from the recipient's point of view.
Information gained will be useful in the planning of cancer services.


Publications to date:

Balmer, CE, Osborne RJ. Investigating the patient's perspective of the clinical utility of second-line chemotherapy. Eur J Onc Nurs 1998: 2; 64-66

Balmer CE, Thomas P, Osborne RJ.  Who wants second-line palliative chemotherapy?  Psycho-Oncology 2001; 10: 410-418

Further information can be obtained from:

Dr Richard Osborne
Consultant in Medical Oncology
Poole Hospital NHS Trust
The Dorset Cancer Centre
Longfleet Road

Dorset   BH15 2JB



All contents copyright Department of Health. All rights reserved.
Page maintained by Helen Bailey

Last updated 22 November 2004
This page looks best when viewed with either MS Internet Explorer or Netscape Navigator